A Prospective, Multicenter, Randomized Controlled Clinical Study on the Safety and Efficacy of Biolimus Drug-Coated Balloon (DCB) Versus Drug-Eluting Stent (DES) in the Treatment of De Novo Coronary Artery Lesions

General Inclusion Criteria: 1. Patients aged ≥ 18 years and ≤ 80 years; 2. Patients with stable angina, unstable angina, old myocardial infarction, or asymptomatic myocardial ischemia with objective evidence; 3. Patients without contraindications to coronary revascularization (PCI or CABG); 4. Patients who can understand the study purpose, voluntarily participate in the trial, sign the informed consent form, and are willing to complete follow-up as required by the protocol. Angiographic Inclusion Criteria: 1. The target lesions are de novo native coronary artery lesions, located in 1 or 2 different coronary arteries; the number of target lesions in each coronary artery shall not exceed 1 (for two-vessel disease, a maximum of 2 target lesions are permitted). 2. All target lesions shall meet the following requirements: ① The reference vessel diameter is between 2.25 mm and 4.0 mm, and the lesion length ≤ 30 mm; ② The visual estimated stenosis degree before procedure ≥ 70%, or ≥ 50% with documented ischemic evidence; ③ Successful pre-dilation: defined as no NHLBI type C or higher dissection; TIMI flow grade 3; residual stenosis ≤ 30%. 3. Each target lesion is only allowed to be treated with one investigational device or control device (except for bailout stent implantation). 4. If the patient has non-target lesions requiring concurrent intervention, such non-target lesions shall be successfully treated prior to the treatment of target lesions.